PIPERNO-NEUMANN , S.

Last name: PIPERNO-NEUMANN

First name: S.

February 29, 2024 (v1)

Publication

Metadata-only

Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis

Piulats, J. M. Watkins, C. Costa García, M.

Background: Tebentafusp demonstrated a superior overall survival (OS) benefit [hazard ratio (HR) 0.51] compared to investigator's choice (82% pembrolizumab) in a randomized, phase III trial (IMCgp100-202; N ¼ 378) in untreated metastatic uveal melanoma (mUM). The 1-year OS rates for tebentafusp and pembrolizumab were 73% and 59%, respectively....

Uploaded on: March 3, 2024
August 2021 (v1)

Journal article

Metadata-only

A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery

Pautier, P. Floquet, A. Chevreau, C.

Background: Uterine leiomyosarcomas (U-LMSs) and soft tissue leiomyosarcomas (ST-LMSs) are rare tumours with poor prognosis when locally advanced or metastatic, and with moderate chemosensitivity. In 2015 we reported very encouraging results of the LMS-02 study (NCT02131480) with manageable toxicity. Herein, we report the updated and long-term...

Uploaded on: December 3, 2022
April 2022 (v1)

Journal article

Metadata-only

Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG)

Moreau-Bachelard, C. Campion, L. Toulmonde, M.

Background: Synovial sarcoma (SS) occurs in both adult and pediatric patients. The primary aim of this study is to describe the outcomes, prognostic factors, and treatment of patients with metastatic SS within a nationwide cohort.Patients and methods: All pediatric and adult patients with metastatic SS are registered in the French Sarcoma Group...

Uploaded on: December 3, 2022

PIPERNO-NEUMANN , S.

Recent uploads